In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
US11597917B2 · kind B2 · utility
0Cited by
14References
26Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 6, 2018 |
| Grant date | Mar 7, 2023 |
| Priority date | — |
| Expiry date | Jul 26, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/205
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.